Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Rochester
With
Roswell Park Cancer Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologic diagnosis of prostate cancer
Age 18 yrs or older
Able to provide written, informed consent
Subjects with castration resistant prostate cancer, as defined by having testosterone level of less than 50 Nano gram/dl, being treated with enzalutamide with a rise in PSA, confirmed with a repeat measurement within 1 to four weeks, or asymptomatic radiographic progression
You may not be if
Subjects with estimated glomerular filtration rate of less than 50 ml/min
Subjects with hearing impairment. The treating physician may decide which subjects should not receive cisplatin based on audiometry or based on clinical judgment.
Subjects with grade 2 or greater neuropathy
Subjects who in the opinion of the treating physician could not tolerate the standard hydration before receiving cisplatin
Chemotherapy naïve subjects who in the opinion of the treating physician should receive docetaxel instead of enrolling on the trial and receive cisplatin
